'Catch-Up’ Symptoms Slow Perrigo In Cold Season
Executive Summary
Strong cough/cold season forecast bodes well for upper respiratory and other OTCs Perrigo provides as private label and store brand products, but it isn’t expecting to capitalize in the Americas due to lingering impacts from supply chain and production disruptions linked to the COVID-19 pandemic.
You may also be interested in...
Perrigo Results Reach A Valley Before Peak Expected From Opill Launch, Private Label Gains
Perrigo investing in preparing marketplace for Opill and educating consumers about it and reports trend of sales volumes increasing for private label/store brand consumer health portfolio.
US Q4 Consumer Health Earnings Preview: Will Demand Or Shortage Have More Impact?
Demand for OTC pain relievers and cough/cold products jumped prior to October-December and remained high during quarter due to consumer concern not only about flu but also RSV and additional COVID-19 mutation. US and Canadian firms marketing OTC drugs and supplements also will be offering additional signals on planned spinoffs of consumer health businesses.
Perrigo Adds Good Start Brand In $230M Statement On Boosting Infant Formula Production Capacity
Good Start formula line marketed in US and in Canada will move to Perrigo from Nestle along with a formula plant in Wisconsin, where Perrigo will expand current 29mil pound annual production capacity to 36m within 18 months. Good Start available in US as part of iconic Gerber brand and under Nestle brand in Canada.